FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	S'
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cloonan Michael						2. Issuer Name and Ticker or Trading Symbol Sage Therapeutics, Inc. [SAGE]									(Chec	k all applic Directo	cable) r	g Pers	on(s) to Iss 10% Ov Other (s	vner	
	`	APEUTICS, INC.	(Middle)												below)	peany					
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)					_	Line											ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(-			n Dori	· otiv	۰ ۲۰	ourit	ioo Ao		rad D	io.	20004.0	f or Bo	nofic	مالمان	Owned					
Table I - Non-Deriv. 1. Title of Security (Instr. 3) 2. Transa Date (Month/D			saction	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		, 3. T	ransact	ion	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			or 5. Amou 4 and Securitie Benefici Owned F		nt of es ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									C	ode V	,	Amount	(A) o	r _{Pr}	ice	Reported Transact (Instr. 3 a	ion(s)	n(s) d 4) (Instr. 4)			
Common	Stock			05/2	2/201	9				М		25,000	0 A	\$	73.43	25,4	161 ⁽¹⁾	D			
Common	Stock			05/2	2/201	9				S ⁽²⁾		25,000	0 D	5	\$175	461(1)		D			
		-	Гable II -									sed of, onvertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,		ansaction ode (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate Exei iration I nth/Day	ate	ble and	7. Title and Amou of Securities Underlying Derivative Securit (Instr. 3 and 4)		[B. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	/e es ally ng d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e rcisable		xpiration ate	Title	Amo or Num of Shar	ber						
Stock Option	\$73.43	05/22/2019			M			25,000		(3)	0	5/01/2027	Common	25,	000	\$0.00	160,00	00	D		

Explanation of Responses:

- 1. The 461 shares reported as beneficially owned were acquired by the reporting person pursuant to the issuer's employee stock purchase plan.
- 2. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- 3. The securities awarded on 5/01/2017 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2016 Inducement Equity Plan. Options to purchase 46,250 shares of common stock vested on April 24, 2018 with 138,750 shares vesting in 36 equal monthly installments thereafter.

Remarks:

/s/ Anne Marie Cook, as 05/23/2019 Attorney-in-Fact for Michael Cloonan

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.